Annalisa Guida1, Cristina Masini2,3, Michele Milella4, Giuseppe Di Lorenzo5, Matteo Santoni6, Veronica Prati7, Camillo Porta3,8, Laura Cosmai3,9, Donatella Donati10, Cinzia del Giovane11, Pasquale Mighali1, Roberto Sabbatini1,3. 1. Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy. 2. AO Santa Maria Nuova, Reggio Emilia, Italy. 3. Italian Nephro-Oncology Group/Gruppo Italiano di Oncologia Nefrologica (GION), Italy. 4. Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy. 5. Department of Endocrinology & Medical Oncology, Genitourinary Cancer Section, University Federico II, Napoli, Italy. 6. Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti Umberto I, Ancona, Italy. 7. Oncologia Medica a Direzione Universitaria, Fondazione del Piemonte per l'Oncologia, Istituto per la Ricerca e Cura del Cancan Candiolo, Torino, Italy. 8. Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy. 9. UO Nefrologia e Dialisi, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy. 10. Unità Operativa Oncologia, Azienda Ospedaliero-Universitaria, Ferrara, Italy. 11. Statistics Unit, Department of Clinical, Diagnostic & Public Health Medicine, University of Modena & Reggio Emilia, Modena, Italy.
Abstract
AIMS: This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis. PATIENTS & METHODS: From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected. RESULTS: Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported. CONCLUSION: Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.
AIMS: This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis. PATIENTS & METHODS: From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected. RESULTS: Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported. CONCLUSION:Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.
Authors: Łukasz Mielczarek; Anna Brodziak; Paweł Sobczuk; Maciej Kawecki; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka Journal: Cancer Chemother Pharmacol Date: 2021-03-25 Impact factor: 3.333